Open AccessInhibition of Ehrlich ascites cancer, hypoxia-inducible factor-1 alpha, and the kinase insert domain-containing receptor/fms-like tyrosine kinase-binding domains of vascular endothelial growth factor by Thiazole Acetamide Derivatives
Author(s) -
Leelavathi N. Madhu,
Sandeep Telkar,
Divyalaxmi Kamath,
Melita Evan D Souza,
Shama Rao,
Prakash S. Nayak,
B. K. Sarojini
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_577_16
Subject(s) - vascular endothelial growth factor , tyrosine kinase , cancer research , kinase insert domain receptor , biology , docking (animal) , kinase , chemistry , vascular endothelial growth factor a , microbiology and biotechnology , signal transduction , biochemistry , medicine , vegf receptors , nursing
Tumor cells that have the ability to express vascular endothelial growth factor (VEGF) are more competent to growth and metastasize by the adequate amount of blood and oxygen supply by the blood vessels to the growing mass of cells. Hypoxic tumors are known for its aggressiveness and resistance to the treatment. Targeting VEGF and hypoxia-inducible factor-1 alpha (HIF-1α) is an attractive strategy to interrupt the multiple pathways crucial for tumor growth. In the present study, two thiazole acetamide derivative's anticancer property, anti VEGF and HIF-1α inhibitory property were investigated.